Form 4: Director Arduini Acquires BMY Deferred Share Units

Bristol-Myers Squibb Director Peter J. Arduini is set to acquire 625.695 deferred share units in a pre-planned transaction.

Summary

• Peter J. Arduini, a Director at Bristol-Myers Squibb Co (BMY), is scheduled to acquire 625.695 Deferred Share Units on December 31, 2025, as part of a pre-planned arrangement under Rule 10b5-1(c).
• Each Deferred Share Unit will convert into one share of BMY common stock upon settlement, which typically occurs when the reporting person ceases to be a director or at a future date specified by the director.
• Following this future acquisition, Arduini's beneficial ownership of derivative securities will total 66,116.446, including deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: A routine, positive event indicating increased director alignment with shareholder interests through equity compensation, with no negative implications.

Positives

• Director Peter J. Arduini is increasing his beneficial ownership in Bristol-Myers Squibb Co by acquiring 625.695 Deferred Share Units, aligning his interests with shareholders.
• The transaction is pre-planned under Rule 10b5-1(c), indicating a structured and transparent approach to equity compensation.

Risks

• The future value of the Deferred Share Units is subject to the market price fluctuations of Bristol-Myers Squibb common stock.

Future Outlook

The filing details a pre-planned acquisition of Deferred Share Units by a director on December 31, 2025, under a Rule 10b5-1(c) plan. This indicates a structured, long-term approach to director compensation, aligning future incentives with the company's performance and shareholder value.

Industry Context

This type of equity compensation, specifically Deferred Share Units, is a common practice in the pharmaceutical and biotechnology industry for non-employee directors, aiming to align their long-term interests with shareholder value.

Comparison to Industry Standards

• The use of Deferred Share Units (DSUs) as a component of non-employee director compensation is a standard practice across large-cap pharmaceutical companies, similar to practices at Pfizer, Merck, and Johnson & Johnson.
• The structure, where DSUs convert to common stock upon cessation of directorship or a specified future date, is typical for promoting long-term commitment and aligning director interests with shareholder returns.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with long-term shareholder value due to equity-based compensation.

Next Steps

• The Deferred Share Units will convert into common stock upon the reporting person ceasing to be a director or at a future date previously specified by the reporting person.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of deferred share units by a director as part of their compensation plan. While it indicates alignment of interests, it does not present new information significant enough to alter an investment recommendation for Bristol-Myers Squibb Co.

Keywords

Bristol-Myers Squibb, BMY, Form 4, Deferred Share Units, Director Compensation, Insider Ownership, Equity Compensation, Peter J. Arduini, Rule 10b5-1